Global Hepatitis B Treatment Market Research Report, By Type (Acute and Chronic), Treatment (Immune Modulator Drugs, Antiviral Drugs, Vaccine, and Surgery (Liver Transplant)), and Distribution Channel (Hospital & Retail Pharmacies)—Forecast till 2024
Market Highlights
The global hepatitis B treatment market is expected to grow at an approximate CAGR of 5.3% during the forecast period, 2018–2024.
Hepatitis B is a viral infection caused by a hepatitis B virus. This infection lasts for a longer period and can cause many other complications, such as scarring in the liver, liver cancer or liver failure. The person suffering from hepatitis B faces various symptoms such as fever, fatigue, nausea, and muscle aches.
The other symptoms include jaundice, swelling in the legs, poor appetite, drowsiness and many more. The key factors contributing the market growth are growing geriatric population, increasing the prevalence of viral infection and growing sexually transmitted diseases among the population contribute to driving the market growth. The World Hepatitis Alliance (WHA), 2017 reported that 52 million children across the world are living with viral hepatitis. Such a huge population suffering from Hepatitis boosts the market growth.
However, the factor such as the side effects or complication caused due to treatment may hamper the market growth.
Avail a Free Sample@ https://www.marketresearchfuture.com/sample_request/7817
Segmentation
The global hepatitis B treatment market is segmented on the basis of type, treatment, distribution channel, and region.
Based on type, the market is segmented into acute and chronic. On the basis of treatment, the global hepatitis B treatment market is segmented into immune modulator drugs, antiviral drugs, vaccine, and surgery (liver transplant). The immune modulator drugs are further sub-segmented into pegylated interferon and interferon alpha. The antiviral drugs are sub-segmented into tenofovir disoproxil, entecavir, telbivudine, lamivudine, and others. By distribution channel, the market is segmented into hospital & retail pharmacies and online pharmacies.
Regional Analysis
The Americas dominates the global market for hepatitis B treatment. Factors such as the presence of a large number of healthcare companies, increasing geriatric population and high healthcare expenditure among the population within the Americas drives the market. The National Vaccine Information Center reported 3,370 cases of hepatitis B were reported in the US in 2015.
Following similar trends, Europe stood second in the global hepatitis B treatment market. The increased prevalence of viral diseases and growing healthcare expenditure in this region boost market growth. Also, the presence of developed economies, increasing healthcare facilities, and rising government funding for healthcare boost market growth. Asia Pacific was the fastest growing region for the global hepatitis B treatment market in 2017. This can be attributed due to the increasing incidences of HIV infection and rising demand for the treatment of viral infection among the population boosts market growth.
On the other hand, the Middle East and Africa holds the least share in the global hepatitis B treatment market. The poor economies within the African region and lack of awareness about the treatment methods hinder the market growth.
Intended Audience
- Pharmaceutical Companies
- Biotechnological Institutes
- Government and Private Laboratories
- Research and Development (R&D) companies
- Medical Research Laboratories
Access Report Details @ https://www.marketresearchfuture.com/reports/hepatitis-b-treatment-market-7817
The report for Global market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.
Key Players
Some of the key players in the global hepatitis B treatment market are Accord Healthcare Inc., Apotex Corp., Arbutus Biopharma, Arrowhead Pharma, Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline, Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Par Pharmaceutical, Inc., Teva Pharmaceuticals, Zydus Pharmaceuticals, and others.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact Us:
Market Research Future
Phone: +1 646 845 9312
Email: [email protected]
The global Hepatitis B Treatment Market is expected to grow at an approximate CAGR of 5.3% during the forecast period, 2018–2024.Hepatitis B is a viral infection caused by a hepatitis B virus.
The other symptoms include jaundice, swelling in the legs, poor appetite, drowsiness and many more.
Global Hepatitis B Treatment Market: Competitive LandscapeSome of the key players in the global Hepatitis B Treatment Market areAccord Healthcare Inc.Apotex Corp.Arbutus BiopharmaArrowhead PharmaAurobindo Pharma LimitedBristol-Myers Squibb CompanyGilead Sciences, Inc.GlaxoSmithKlineLupin Pharmaceuticals, Inc.Merck & Co., Inc.Par Pharmaceutical, Inc.Teva PharmaceuticalsZydus PharmaceuticalsHepatitis B Treatment Market SegmentationThe global Hepatitis B Treatment Market is segmented on the basis of type, treatment, distribution channel, and region.Based on type, the market is segmented into acute and chronic.
Also, the presence of developed economies, increasing healthcare facilities, and rising government funding for healthcare boost market growth.
Asia Pacific was the fastest growing region for the global Hepatitis B Treatment Marketin 2017.
On the other hand, the Middle East and Africa holds the least share in the global Hepatitis B Treatment Market market.
